On April 7, Shenzhen Bay Laboratory Pingshan Translational Medicine Center（PTMC）and Pengcheng Laboratory Shennong Platform held a cooperation agreement signing and joint laboratory opening ceremony at the Industry-Academia-Research Base in Pingshan High-tech Zone. Li Zigang, Executive Director of Pingshan Translational Medicine Center, and Chen Jie, Head of Pengcheng Shennong Platform, attended the ceremony and unveiled the plaque. Both sides plan to cooperate in various areas within five years to establish a platform for in-depth intelligent drug design and development based on international cutting-edge artificial intelligence algorithms, to achieve rapid follow-up and catch-up with international leading polypeptide and small molecule innovative drug development technologies, and to establish a high-quality intelligent drug development database.
Li Zigang expressed his pleasure to reach a cooperation with Shennong Platform. With AI technology, the efficiency of new drug development such as protein structure prediction, drug target discovery, new drug molecule design and experiment design would be significantly enhanced, and the PTMC would actively cooperate with Shennong Platform in the training of research AI that could predict polypeptide and protein structure stability, providing training materials and correcting prediction results to further enhance the efficiency of new drug results translation.
Chen Jie expressed that Shennong Platform had strong generalization ability and the industrial AI development model of pre-training + tasks fine-tune would accelerate its application in the industry greatly. He hoped to cooperate with PTMC to further enhance the specialization of AI in the biomedical field and to improve the prediction accuracy of AI in a wider and more complex new drug development scenario, so as to help pharmaceutical companies to achieve “corner overtaking”.
Both sides planned to cooperate in various fields within five years to establish an in-depth intelligent drug design and research platform based on international cutting-edge artificial intelligence algorithms, to achieve rapid follow-up and catch-up with international leading polypeptide and small molecule innovative drug research and development technologies, and to establish a high-quality intelligent drug research and development database. The key areas of collaboration would include AI-enabled polypeptide drug development, AI-enabled small molecule drug development, establishment of an intelligent drug development database, etc.
PTMC has been actively strengthening the top-level design of pharmaceutical creation, laying out a next-generation intelligent new drug research and development system, reinforcing the application of the "AI+" model in the field of new drug research and development with the establishment of the joint laboratory, accelerating the translation of new drug creation results to the ground, and guarding life and health with technological innovations.
